Lazard Asset Management LLC Rigel Pharmaceuticals Inc Transaction History

Lazard Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.12 - $1.57 $48,014 - $67,305	-42,870 Reduced 92.9%	3,278 $4,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $33,226 - $71,990	46,148 New	46,148 $66,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $49,800 - $79,680	39,840 New	39,840 $52,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $45,548 - $505,177	41,408 New	41,408 $48,000
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $59,808 - $76,896	-17,088 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $57,244 - $84,243	17,088 New	17,088 $58,000
Q3 2020 Nov 13, 2020	SELL	$1.78 - $4.13 $45,669 - $105,963	-25,657 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$1.41 - $2.05 $36,176 - $52,596	25,657 New	25,657 $46,000
Q1 2020 May 14, 2020	SELL	$1.27 - $3.0 $9,328 - $22,035	-7,345 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.6 - $2.43 $11,752 - $17,848	7,345 New	7,345 $15,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.8B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.